FDA Approves APHEXDA — Gamida Cell Inc.

# FDA Approves Gamida Cell's APHEXDA for Hematopoietic Stem Cell Mobilization Gamida Cell Inc. received FDA approval for APHEXDA (motixafortide acetate), a subcutaneous injection designed to mobilize hematopoietic stem cells, potentially expanding the company's presence in the cell therapy and transplantation markets. The approval could strengthen Gamida Cell's competitive position in stem cell mobilization, an area with limited treatment options and growing demand from the expanding cell and gene therapy sector.